September 17, 2024 01:00 AM EDTUpdated 06:31 AM
Startups
R&D

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

Kyle LaHucik

Senior Reporter

BARCELONA — A month af­ter gut­ting its in­ter­nal drug dis­cov­ery group, 23andMe is trudg­ing along with the ex­per­i­men­tal med­i­cines it’s al­ready brought …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times